Health Policy

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Trump's Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess

EMA scientific advice volumes hit a record in the first half of 2026. The agency is planning pre-payment at submission, an agile advice pilot for 2027, and a regulatory sandbox workshop in September. #SyenzaNews #EMA #MarketAccess #DrugDevelopment

Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess

The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

A new benchmark in npj Digital Medicine finds frontier AI models at near-perfect accuracy on German medical licensing exams, yet image questions still cut their scores far more than for students. #SyenzaNews #AIinHealthcare #DigitalHealth

The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma

Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews